KYMR Q1 2024 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+8.7% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$58M-562.2% margin

Net Income

-$49M-472.0% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-78.5%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$47M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$868M

Total Liabilities

$157M

Stockholders' Equity

$711M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$9M	+8.7%
Gross Profit	$10M	$9M	+8.7%
Operating Income	-$58M	-$45M	-27.6%
Net Income	-$49M	-$41M	-18.6%